Victoza approval vital
October 5, 2010
THE November meeting of the
Pharmaceutical Benefits Advisory
Committee will be crucial for Novo
Nordisk’s Victoza (liraglutide),
according to industry analysis
group Datamonitor.
Spokesperson Lisette Oversteegen
said the consideration of the
glucagon-like peptide-1 diabetes
treatement is “uncertain,
considering that it took three years
to get Byetta on the PBS.”
The November PBAC agenda
also includes consideration of
Novartis’ Galvumet (vildagliptin/
metformin).
Victoza has already shown
“significant benefits over Byetta,
including its once-daily
administration compared to
Byetta’s twice-daily dosing,”
Oversteegen said.
Also in the wings is Eli Lilly’s
once-weekly Bydureon formulation
of exenatide which is expected to
launch after 2011.
“It is therefore vital for Novo
Nordisk to receive PBS listing for
Victoza on its first try in November,”
Datamonitor said, with the
company requesting that
reimbursement be made available
for its product in dual and triple
combination therapy with
metformin and a sulfonylurea.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Oct 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Oct 10
